Our results revealed that a single dose of Pazopanib mimics the anti-VEGF/VEGFR impact on tumors subsequently exposed to SDRT, increasing ASMase activity in the serum and tumor endothelial dysfunction, enhancing tumor response, and exhibiting critical dependence on timing relative to SDRT exposure. This evidence concerns the gene SMPD1 and neoplasm.